Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease.
Limited data has been published on the treatment results in patients with light-chain deposition disease (LCDD). Whenever possible, high-dose melphalan followed by autologous stem cell transplantation (ASCT) has been the first treatment option, achieving somehow better results than conventional therapy. However, and based on the promising results obtained by treating patients with light-chain amyloidosis with bortezomib/dexamethasone, new treatment options appear in LCDD. Herein, we describe three patients with LCDD treated with bortezomib/dexamethasone followed by high-dose melphalan and autologous transplantation. We believe that this new approach should be the treatment of choice in this disease. In addition, those patients achieving hematologic complete response after ASCT could benefit from a kidney transplant if the renal impairment requiring dialysis persists.
Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic, Barcelona, Spain.
Natalia
N
Tovar
Ma Teresa
MT
Cibeira
Laura
L
Rosiñol
Manel
M
Solé
Carlos Fernández
CF
de Larrea
Lourdes
L
Escoda
Montserrat
M
Rovira
Joan
J
Bladé
D000328:Adult; D001897:Boronic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D000069286:Bortezomib; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use*
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone